Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML

Trial Profile

Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Celator Pharmaceuticals; Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 19 Jul 2018 Results published in the Journal of Clinical Oncology
    • 19 Jul 2018 According to Jazz Pharmaceuticals plc media release, Data from the study formed the basis of the FDA application and the Marketing Authorization Application (MAA) to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
    • 19 Jul 2018 event According to a Jazz Pharmaceuticals medis release, data from this trial were published online in the Journal of Clinical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top